Last reviewed · How we verify
Dexmedetomidine, Midazolam
At a glance
| Generic name | Dexmedetomidine, Midazolam |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Characteristic Electroencephalogram of General Anesthesia
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium (PHASE4)
- Comparison Between Two Drugs in Sedation of Upper GI Endoscopy
- Attenuate the Stress Response in Laparoscopic Cholecystectomy (PHASE4)
- Dexmedetomidine vs Midazolam in Coronary Artery By-pass Surgery (NA)
- Electrophysiologist-led Deep Sedation Protocols for Pulsed Field Ablation for Atrial Fibrillation Using a Bipolar Tip-Catheter: The DEEP-PFA Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine, Midazolam CI brief — competitive landscape report
- Dexmedetomidine, Midazolam updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI